OSU6162
Phase 2Small molecule
OSU6162 is one of 11 small molecule programs targeting Bipolar Depression. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Bipolar Depression
#DrugCompanyPhaseTrials
1Vraylar
AbbVieApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Ulotaront
IIntra-Cellular Therapies, Inc.
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Latuda
SSunovion Respiratory Development Inc.
Approved
Rexulti
OtsukaApproved
Epidiolex
Jazz PharmaceuticalsPhase 3
Advil
KKenvue Brands
Phase 2
Azetukalner
XXenon Pharmaceuticals Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OSU6162. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGöteborg University